Berberine: study protocols
12 study groups say how much Berberine participants took a day. These are the doses the studies gave. They are not a recommendation.
Dose per serving from products
258 products in our catalogue print how much Berberine a serving holds.
Most common: 250 mg to 500 mg, 25% of 258 products.
| Dose per serving | Products |
|---|---|
| 2.5 mg to 5 mg | 23 |
| 5 mg to 10 mg | 13 |
| 10 mg to 25 mg | 15 |
| 25 mg to 50 mg | 28 |
| 50 mg to 100 mg | 19 |
| 100 mg to 250 mg | 54 |
| 250 mg to 500 mg | 65 |
| 500 mg to 1 g | 19 |
| 1 g to 2.5 g | 21 |
| over 2.5 g | 1 |
Dose per serving from research
12 study groups in 10 studies say how much Berberine participants took a day.
These are the doses the studies gave. They are not a recommendation.
Most common: 500 mg to 1 g, 67% of 12 study groups.
| Daily dose | Study groups |
|---|---|
| 250 mg or less | 1 |
| 250 mg to 500 mg | 0 |
| 500 mg to 1 g | 8 |
| 1 g to 2.5 g | 3 |
Commonly used together
None of these 12 study groups took Berberine with anything else.
12 study groups
| Study | |||
|---|---|---|---|
| Berberine versus placebo for the prevention of recurrence of colorectal adenoma: a multicentre, double-blinded, randomised controlled study 2020 · berberine group · Adults aged 18–75 with one to six histologically confirmed colorectal adenomas removed by polypectomy | 600 mg | 2 years | 553 |
| A randomized, multicenter and noninferiority study of amoxicillin plus berberine vs tetracycline plus furazolidone in quadruple therapy for Helicobacter pylori rescue treatment 2020 · berberine and amoxycillin (BA)-based quadruple therapy group · Adults aged 18–70 years, either sex, with H. pylori infection whose eradication treatment had previously failed at least once | 900 mg | 2 weeks | 329 |
| Efficacy and safety of triple therapy containing berberine hydrochloride, amoxicillin, and rabeprazole in the eradication of Helicobacter pylori 2022 · berberine triple scheme (observation group) · Adults aged 18–70 with initial Helicobacter pylori infection and dyspepsia, who had not previously received eradication therapy | 900 mg | 2 weeks | 262 |
| Berberine containing quadruple therapy for initial Helicobacter pylori eradication: An open-label randomized phase IV trial 2017 · berberine-containing quadruple therapy · Adults aged 18–70 with documented Helicobacter pylori infection and upper gastrointestinal symptoms | 200 mg | 2 weeks | 304 |
| Berberine Ursodeoxycholate for the Treatment of Type 2 Diabetes: A Randomized Clinical Trial 2025 · 500-mg group · Adults aged 41-76 with type 2 diabetes | 1 g | 12 weeks | 37 |
| Berberine Ursodeoxycholate for the Treatment of Type 2 Diabetes: A Randomized Clinical Trial 2025 · 1000-mg group · Adults aged 41-76 with type 2 diabetes | 2 g | 12 weeks | 38 |
| Effects of berberine on the blood concentration of cyclosporin A in renal transplanted recipients: clinical and pharmacokinetic study 2005 · BBR-treated group · Renal-transplant recipients receiving cyclosporin A | 600 mg | 90 days | 52 |
| Repeated administration of berberine inhibits cytochromes P450 in humans 2012 · berberine capsules · Healthy Chinese male volunteers, mean age 21.6 years; no stated condition | 900 mg | 2 weeks | 18 |
| Berberine is an insulin secretagogue targeting the KCNH6 potassium channel 2021 · BBR treatment · Healthy men aged 18–45 years with normal glucose tolerance | 1 g | 1 day | 15 |
| Effects of berberine on the blood concentration of cyclosporin A in renal transplanted recipients: clinical and pharmacokinetic study 2005 · Pharmacokinetic study BBR co-administration phase · Six renal-transplant recipients receiving cyclosporin A | 600 mg | 12 days | 6 |